Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The company reported strong growth in its 2025 mid-year results, driven by dual business segments: consumer products and medical supplies. The revenue for the first half of 2025 reached 5.296 billion yuan, a year-on-year increase of 31.31%, while the net profit attributable to shareholders was 492 million yuan, up 28.07% year-on-year [7] - The consumer products segment showed robust performance, with revenue of 2.745 billion yuan in the first half of 2025, a year-on-year increase of 20.3%. The company experienced significant growth in its core product categories, particularly in sanitary napkins and cotton soft towels [7] - The medical supplies segment also performed well, with revenue of 2.515 billion yuan in the first half of 2025, a year-on-year increase of 46.39%. The company is focusing on internal growth and mergers to enhance its market position [7] - The company has adjusted its profit forecasts for 2025-2027, increasing the net profit estimates to 1.045 billion yuan, 1.237 billion yuan, and 1.494 billion yuan respectively, corresponding to P/E ratios of 23, 20, and 16 [7] Financial Summary - Total revenue for 2023 is projected at 8.185 billion yuan, with a year-on-year decrease of 27.89%. However, revenue is expected to grow to 11.219 billion yuan in 2025, reflecting a year-on-year increase of 24.96% [1][8] - The net profit attributable to shareholders is forecasted to rise from 580.4 million yuan in 2023 to 1.045 billion yuan in 2025, representing a year-on-year growth of 50.21% [1][8] - The latest diluted EPS is expected to increase from 1.00 yuan in 2023 to 1.79 yuan in 2025 [1][8] - The company's cash flow from operating activities for the first half of 2025 was 340 million yuan, a year-on-year increase of 75.82%, indicating strong cash generation capabilities [7]
稳健医疗(300888):2025年中报点评:双主业并驾齐驱,稳健向好